Get startedLog in
    Picture of Paradigm Biopharmaceuticals logo

    PAR — Paradigm Biopharmaceuticals Income Statement

    0.000.00%
    au flag iconLast trade - 00:00
    HealthcareSpeculativeSmall Cap
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual income statement for Paradigm Biopharmaceuticals, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.

    C2022
    June 30th
    2023
    June 30th
    R2024
    June 30th
    2025
    June 30th
    2026
    June 30th
    Period Length:12 M12 M12 M12 M12 M
    Source:ARSARSARSARSARS
    Standards:
    IFRS
    IFRS
    IFRS
    IFRS
    IFRS
    Status:FinalFinalFinalFinalFinal
    Revenue
    Total Revenue7.898.496.447.118.12
    Cost of Revenue
    Gross Profit7.758.476.437.088.11
    Selling / General / Administrative Expenses
    Research And Development
    Unusual Expense / Income
    Other Operating Expenses
    Total Operating Expenses486065.125.961.2
    Operating Profit-40.1-51.5-58.7-18.8-53.1
    Total Net Non Operating Interest Income / Expense
    Gain / Loss on Sale of Assets
    Total Net Non Operating Interest Income / Expense
    Net Income Before Taxes-39.2-51.9-58.7-18.8-56.3
    Provision for Income Taxes
    Net Income After Taxes-39.2-51.9-58.7-18.8-56.3
    Net Income Before Extraordinary Items
    Net Income-39.2-51.9-58.7-18.8-56.3
    Income Available to Common Shareholders Excluding Extraordinary Items
    Income Available to Common Shareholders Including Extraordinary Items
    Diluted Net Income-39.2-51.9-58.7-18.8-56.3
    Diluted Weighted Average Shares
    Basic EPS Including Extraordinary Items
    Diluted EPS Including Extraordinary Items
    Diluted EPS Excluding Extraordinary Items
    Normalised Income Before Taxes
    Normalised Income After Taxes
    Normalised Income Available to Common Shareholders
    Diluted Normalised EPS-0.163-0.18-0.168-0.042-0.096
    Dividends per Share